Рецепт. 2022; : 76-84
Психоэмоциональные последствия коронавирусной инфекции
https://doi.org/10.34883/PI.2022.25.1.006Аннотация
В статье описаны предрасполагающие факторы и клинические проявления психоэмоциональных нарушений, вызванных коронавирусной инфекцией COVID-19 (COronaVIrus Disease 2019). Группами риска развития психических нарушений являются медицинские работники, оказывающие помощь пациентам с COVID-19; люди, потерявшие родственников и близких, а также те, кто понес значительные финансовые потери и лишился места работы. Рассматриваются подходы к терапии психоэмоциональных нарушений: психотерапия и фармакотерапия, которые должны быть направлены на купирование тревоги, восстановление сна, лечение депрессии и иных психических отклонений. Своевременное проведение психотерапии и фармакотерапии психоэмоциональных нарушений необходимо, поскольку предполагается, что данный синдром будет снижать работоспособность и качество жизни человека.
Список литературы
1. Alexandrovsky Yu. (1996) Social stress disorders. RMJ, pp. 117–126 (in Russian).
2. Atlantis E., Fahey P., Cochrane B., Smith S. (2013) Bidirectional associations between clinically relevant depression or anxiety and chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. Chest, pp. 766–777.
3. Brady F., Warnock-Parkes E., Barker C., Ehlers A. (2015) Early in-session predictors of response to trauma-focused cognitive therapy for posttraumatic stress disorder. Behav Res Ther., pp. 40–47.
4. Coronavirus disease 2019 (COVID-19). World Health Organization Situation Report. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports//20200305-sitrep-45-covid-19.pdf (accessed 17.07.2021).
5. COVID-19 Strategy Update. World Health Organization. Available at: https://www.who.int/publications-detail/covid-19-strategy-update-14-april-2020 (accessed 14.07.2021).
6. Coronavirus disease 2019 (COVID-19). World Health Organization Situation Report. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports//20200305-sitrep-45-covid-19.pdf (accessed 17.07.2021).
7. Charney D. (2004) Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. American Journal of Psychiatry, pp. 195–216.
8. Gesto M., López-Patiño M.A., Hernández J. (2013) The response of brain serotonergic and dopaminergic systems to an acute stressor in rainbow trout: a time course study. Journal of Experimental Biology, pp. 4435–4442.
9. Gilbertson M.W., Shenton M.E., Ciszweski A. (2002) Smaller hippocampal volume predicts pathological vulnerability to psychological trauma. Nat Neurosci, pp. 1242–1247.
10. Harvey B.H., Oosthuizen F., Brand L. (2004) Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology, pp. 494–502.
11. Lee T.W., Yu Y.W., Chen M.C., Chen T.J. (2011) Cortical mechanisms of the symptomatology in major depressive disorder: A resting EEG study. Journal of Affective Disorders, pp. 243–250.
12. Mathew A.R., Cook J.W., Japuntich S.J., Leventhal A.M. (2015) Post-traumatic stress disorder symptoms, underlying affective vulnerabilities, and smoking for affect regulation. Am J Addict., pp. 39–46.
13. Manna C.B., Tenke C.E., Gates N.A. (2010) EEG Hemispheric Asymmetries during Cognitive Tasks in Depressed Patients with High versus Low Trait Anxiety. Clinical EEG and Neuroscience, pp. 196–202.
14. Mathersul D., Williams L.M., Hopkinson P.J., Kemp A.H. (2008) Investigating models of affect: relationships among EEG alpha asymmetry, depression and anxiety. J BiolPsychol., pp. 560–572.
15. Pollack M.H., Naomi M. Simon, John J. Worthington (2003) Otto Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder. J Psychopharmacol., vol. 17, pp. 276–82.
16. Sandifer P.A., Walker A.H. (2018) Enhancing Disaster Resilience by Reducing Stress-Associated Health Impacts. Front Public Health, pp. 373–385.
17. Shinfuku N. (2002) Disaster mental health: lessons learned from the Hanshin Awaji earthquake. World Psychiatry, pp. 158–159.
18. Retyunskij K., Hmeleva I., Mal’kova E. (2005) Psihiatriya i psihofarmakologiya, 6, pp. 15–22.
19. CHahava V., Less YU., Malygin YA. (2006) Effektivnost’ primeneniya Reksetina u bol’nyh s generalizovannym trevozhnym rasstrojstvom [Efficacy of Rexetine in Patients with Generalized Anxiety Disorder]. Russkij medicinskij zhurnal, p. 16 (in Russian).
20. Fastovcov G., Sokolova E. (2012) PTSR i komorbidnye psihicheskie rasstrojstva [Post-traumatic Stress Disorder (PTSD) and comorbid psychiatric disorders]. Rossijskij psihiatricheskij zhurnal, pp. 77–82 (in Russian).
21. Kirpichenko A. (2016) Ustanovivshayasya praktika primeneniya paroksetina v lechenii pacientov s affektivnymi rasstrojstvami [Generally Accepted Practice of Paroxetine Administration in the Treatment of Patients with Affective Disorders]. Medicinskie novosti, 2, pp. 43–47 (in Russian).
Recipe. 2022; : 76-84
Psychoemotional Consequences of Coronavirus Infection
https://doi.org/10.34883/PI.2022.25.1.006Abstract
The article describes the predisposing factors and clinical manifestations of psychoemotional disorders caused by the coronavirus infection COVID-19 (COronaVIrus Disease 2019). The groups at risk of developing mental disorders are health care workers caring for patients with COVID-19; people who have lost their relatives and loved ones; and those who experienced significant financial losses and lost their jobs. The approaches to the therapy of psychoemotional disorders are considered such as psychotherapy and pharmacotherapy, which should be aimed at relieving anxiety, restoring sleep, treating depression and other mental disorders. Timely psychotherapy and pharmacotherapy of psychoemotional disorders is necessary, since this syndrome is expected to decrease individual’s work performance and quality of life.
References
1. Alexandrovsky Yu. (1996) Social stress disorders. RMJ, pp. 117–126 (in Russian).
2. Atlantis E., Fahey P., Cochrane B., Smith S. (2013) Bidirectional associations between clinically relevant depression or anxiety and chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. Chest, pp. 766–777.
3. Brady F., Warnock-Parkes E., Barker C., Ehlers A. (2015) Early in-session predictors of response to trauma-focused cognitive therapy for posttraumatic stress disorder. Behav Res Ther., pp. 40–47.
4. Coronavirus disease 2019 (COVID-19). World Health Organization Situation Report. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports//20200305-sitrep-45-covid-19.pdf (accessed 17.07.2021).
5. COVID-19 Strategy Update. World Health Organization. Available at: https://www.who.int/publications-detail/covid-19-strategy-update-14-april-2020 (accessed 14.07.2021).
6. Coronavirus disease 2019 (COVID-19). World Health Organization Situation Report. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports//20200305-sitrep-45-covid-19.pdf (accessed 17.07.2021).
7. Charney D. (2004) Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. American Journal of Psychiatry, pp. 195–216.
8. Gesto M., López-Patiño M.A., Hernández J. (2013) The response of brain serotonergic and dopaminergic systems to an acute stressor in rainbow trout: a time course study. Journal of Experimental Biology, pp. 4435–4442.
9. Gilbertson M.W., Shenton M.E., Ciszweski A. (2002) Smaller hippocampal volume predicts pathological vulnerability to psychological trauma. Nat Neurosci, pp. 1242–1247.
10. Harvey B.H., Oosthuizen F., Brand L. (2004) Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology, pp. 494–502.
11. Lee T.W., Yu Y.W., Chen M.C., Chen T.J. (2011) Cortical mechanisms of the symptomatology in major depressive disorder: A resting EEG study. Journal of Affective Disorders, pp. 243–250.
12. Mathew A.R., Cook J.W., Japuntich S.J., Leventhal A.M. (2015) Post-traumatic stress disorder symptoms, underlying affective vulnerabilities, and smoking for affect regulation. Am J Addict., pp. 39–46.
13. Manna C.B., Tenke C.E., Gates N.A. (2010) EEG Hemispheric Asymmetries during Cognitive Tasks in Depressed Patients with High versus Low Trait Anxiety. Clinical EEG and Neuroscience, pp. 196–202.
14. Mathersul D., Williams L.M., Hopkinson P.J., Kemp A.H. (2008) Investigating models of affect: relationships among EEG alpha asymmetry, depression and anxiety. J BiolPsychol., pp. 560–572.
15. Pollack M.H., Naomi M. Simon, John J. Worthington (2003) Otto Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder. J Psychopharmacol., vol. 17, pp. 276–82.
16. Sandifer P.A., Walker A.H. (2018) Enhancing Disaster Resilience by Reducing Stress-Associated Health Impacts. Front Public Health, pp. 373–385.
17. Shinfuku N. (2002) Disaster mental health: lessons learned from the Hanshin Awaji earthquake. World Psychiatry, pp. 158–159.
18. Retyunskij K., Hmeleva I., Mal’kova E. (2005) Psihiatriya i psihofarmakologiya, 6, pp. 15–22.
19. CHahava V., Less YU., Malygin YA. (2006) Effektivnost’ primeneniya Reksetina u bol’nyh s generalizovannym trevozhnym rasstrojstvom [Efficacy of Rexetine in Patients with Generalized Anxiety Disorder]. Russkij medicinskij zhurnal, p. 16 (in Russian).
20. Fastovcov G., Sokolova E. (2012) PTSR i komorbidnye psihicheskie rasstrojstva [Post-traumatic Stress Disorder (PTSD) and comorbid psychiatric disorders]. Rossijskij psihiatricheskij zhurnal, pp. 77–82 (in Russian).
21. Kirpichenko A. (2016) Ustanovivshayasya praktika primeneniya paroksetina v lechenii pacientov s affektivnymi rasstrojstvami [Generally Accepted Practice of Paroxetine Administration in the Treatment of Patients with Affective Disorders]. Medicinskie novosti, 2, pp. 43–47 (in Russian).
